Breaking Finance News

Mast Therapeutics Inc (NASDAQ:MSTX) has been downgraded to Neutral in a report by Laidlaw today.

Boasting a price of $0.12, Mast Therapeutics Inc (NASDAQ:MSTX) traded -81.54% lower on the day. With the last stock price close down -71.25% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Mast Therapeutics Inc has recorded a 50-day average of $0.46 and a two hundred day average of $0.38. Volume of trade was up over the average, with 91,781,043 shares of MSTX changing hands over the typical 4,271,440

Laidlaw has downgraded Mast Therapeutics Inc (NASDAQ:MSTX) to Neutral in a statement released on Wednesday September 21, 2016.

Performance Chart

Mast Therapeutics Inc (NASDAQ:MSTX)

With a total market value of $0, Mast Therapeutics Inc has with a 52 week low of $0.11 and a one year high of $0.71 .

General Company Details For Mast Therapeutics Inc (NASDAQ:MSTX)

Mast Therapeutics, Inc. is a biopharmaceutical company. The Company develops clinical-stage therapies for serious or life-threatening diseases with unmet needs. The Company focuses on developing new therapies for sickle cell disease, a chronic and genetic disorder classified as a rare, or orphan, disease in the United States of America and European Union, and for heart failure, a condition with an unmet need for treatment options. The Company's segment is engaged in the business of developing therapies for serious or life-threatening diseases. The Company focuses on its Molecular Adhesion and Sealant Technology (MAST) platform, to develop MST-188 (vepoloxamer) Injection, its lead product candidate. The Company also develops AIR001, a sodium nitrite solution for intermittent inhalation through nebulizer. The Company's AIR001 is in Phase II clinical development for the treatment of patients with HFpEF.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.